



Proteomics International

LABORATORIES LTD

ASX Release
4 October 2016

ASX code: PIQ

RESEARCH REPORT

Proteomics International Laboratories Ltd (PILL, ASX: PIQ) is pleased to advise that SA Capital has initiated coverage on PILL.

To view a copy of the research report, please visit the company's website:
<http://www.proteomics.com.au/investors/stock-information/>

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Susan Fitzpatrick-Napier [Media Contact]
Digital Mantra Group
T: +61 2 8218 2144
E: team@dmgpr.com

Greg Wood [Financial Advisor]
Managing Director
K S Capital
T: +61 416 076 377
E: g.wood@kscapital.com.au

About Proteomics International Laboratories (PILL)

PILL is an ASX listed (ASX: PIQ) life science company focused on the area of proteomics – the industrial scale study of the structure and function of proteins. PILL is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities located on the QEII Medical Campus in Perth, Western Australia. The Company's business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.

Proteomics International Laboratories Ltd
ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia
T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com